European Commission authorizes Wegovy for weight management across the EU

On 6 January 2022, the European Commission cleared Wegovy for weight management across the European Union, issuing a marketing authorization good in every member state ^[1]. The medicine's active substance is semaglutide, and European regulators concluded its benefits outweigh its risks for the labeled uses ^[1].

Adults fall within the label if their BMI is 30 kg/m² or higher, or between 27 and 30 alongside at least one weight-related condition — diabetes, high blood pressure, abnormal blood fats, obstructive sleep apnoea, or a past heart attack, stroke or blood vessel problem ^[1]. The authorization also reaches adolescents aged 12 and older who weigh more than 60 kg and whose BMI sits at or above the 95th percentile for their age and gender ^[1].

Two versions are approved. The pre-filled pen is injected once a week under the skin of the belly, thigh or upper arm, and patients can give it to themselves by following the package instructions; it is cleared for adults and for adolescents 12 and up ^[1]. The tablet is taken once daily before eating — after at least eight hours without food, then a 30-minute wait before food, drink or other medicines — and is cleared for adults only ^[1]. Either way, the dose rises gradually over 16 weeks to lower the chance of digestive side effects ^[1].

Semaglutide is a GLP-1 receptor agonist. It works like a natural hormone that regulates appetite, so people feel fuller and eat less, with reduced hunger and cravings ^[1].

The largest trial summarized by the European Medicines Agency enrolled 1,961 adults who had tried and failed to lose weight. Those on weekly injections shed an average of 15% of their body weight after 68 weeks; the placebo group averaged 2%. Eighty-four percent of the Wegovy group lost at least 5% of their starting weight, against 31% on placebo ^[1].

A second trial of 611 adults recorded a 16% average drop versus 6% for placebo, with 85% and 48% reaching the 5% mark; everyone in that study also received counseling ^[1]. A third, with 902 participants, gave all of them Wegovy for 20 weeks, then moved part of the group to placebo. Over the next 48 weeks, those still on the drug lost another 8% of their weight, while those switched away regained 7% ^[1].

Among 1,210 adults with type 2 diabetes and a BMI of at least 27, the average reduction at 68 weeks was 10% with Wegovy and 3% with placebo; 67% versus 30% lost at least 5% ^[1].

Adolescent evidence comes from a study of 200 participants aged 12 to under 18, all with obesity except one who was overweight with a related health problem. BMI fell by an average of 16% on Wegovy and rose by just under 1% on placebo; about 73% versus about 18% lost 5% or more of their weight ^[1].

The oral form was tested in 307 adults. Across 64 weeks, tablet users lost roughly 14% of their body weight on average and placebo users roughly 2%; about 76% and about 31% respectively hit the 5% threshold ^[1].

Headache, nausea, vomiting, diarrhea, constipation and abdominal pain are the most common side effects, each listed as possibly affecting more than 1 in 10 people ^[1]. For adolescents, the agency's guidance is to stop treatment if 5% weight loss has not occurred within 12 weeks at the maximum dose or the most they can tolerate ^[1]. Regulators also noted that the data were insufficient to judge how well the injection performs in adolescents who are overweight, and that the tablet has not been studied in that age group ^[1].

Why it matters for patients

The decision gives Wegovy a single approval status across EU member states, with a defined patient population, two ways to take it and one safety profile ^[1]. It does not speak to the United States; American availability, insurance coverage and pricing are outside this record and have not been reported here.

The trial numbers show how widely results vary by group — average losses of about 10% to 16% depending on the population studied, against much smaller averages on placebo ^[1]. The 902-person study is the most direct evidence about what happens when treatment ends: weight came back in the group that stopped, and the assessment notes that people need to keep taking the medicine to avoid regaining weight ^[1]. The two forms also differ in daily routine and in who can use them — a weekly injection for adults and adolescents 12 and older, or a daily fasting tablet for adults only ^[1].

What happens next

Regulators say they monitor Wegovy's use on an ongoing basis, evaluating reported side effects and acting when necessary ^[1]. The medicine overview document was first published on 10 March 2022 ^[1]. The authorization record lists no further EU milestones such as label changes or added age groups, and none has been reported ^[1].